STAb Therapeutics

STAb Therapeutics, a 2018 spin-off from the Research Institute Hospital 12 de Octubre (imas12), is pioneering a novel T cell redirecting immunotherapy. Its STAb platform engineers T cells to secrete T cell engagers (TCEs) in vivo, aiming to enhance anti-tumor responses through sustained drug levels and recruitment of bystander T cells. The company is advancing its lead candidate, STAb-T19 for B-cell malignancies, towards clinical trials, supported by non-dilutive grants from Spanish public entities. It operates as a private, preclinical-stage biotech based in Madrid.

STAb (Secreting T-cell Adoptive therapy) platform: A hybrid immunotherapy that engineers patient T cells to secrete T cell engager (TCE) antibodies in vivo, combining principles of adoptive cell therapy and bispecific antibodies.

STAb Therapeutics competes in the advanced therapy space against approved CD19 CAR-T products (e.g., Novartis's Kymriah, Gilead's Yescarta) and bispecific antibodies (e.g., Amgen's Blincyto). Its differentiation strategy is based on its hybrid platform's potential for improved persistence, broader T cell recruitment, and sustained pharmacokinetics compared to these established modalities.